Search
Vaccines Treatment Options in Canada
A collection of 103 research studies where Vaccines is the interventional treatment. These studies are located in the Canada . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
1 - 12 of 103
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy
Not Yet Recruiting
The goal of this clinical trial is to learn if the RSV vaccine (protects against respiratory syncytial virus) and Tdap vaccine (protects against pertussis) are most effective in pregnant individuals when taken together at the same visit, or separately at different visits. This clinical trial will also learn about the safety and immune responses of these vaccines in pregnancy.
The Main question:
-Is it possible to run a successful trial that tests how safe and effective it is to give Tdap and R... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
07/24/2025
Locations: Vaccine Evaluation Center, Vancouver, British Columbia +3 locations
Conditions: RSV, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Pregnancy, Healthy
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Active Not Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study.
Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
COVID-19 sub-study:
The purpose of... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +295 locations
Conditions: Relapsing Multiple Sclerosis
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
Active Not Recruiting
This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody responses, and the safety of amlitelimab concurrently administered with non-live vaccines in adult participants with moderate-to-severe atopic dermatitis (AD).
The purpose of this study is to compare the immune responses to concomitantly administered Boostrix (tetanus, diphtheria, and acellular pertussis \[Tdap\]) and Pneumovax 23 (PPSV) vaccines in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama +56 locations
Conditions: Dermatitis Atopic
Long-Term PF-06651600 for the Treatment of Alopecia Areata
Active Not Recruiting
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/21/2025
Locations: The University of Alabama at Birmingham Hosptial Outreach Lab, Birmingham, Alabama +143 locations
Conditions: Alopecia Areata
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
Completed
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/28/2025
Locations: GSK Investigational Site, Daphne, Alabama +26 locations
Conditions: Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Completed
Human papillomavirus (HPV) is a member of the Papillomaviridae family of DNA viruses that is capable of infecting humans. HPV infection can cause cancers of the cervix, vulva, vagina, and anus in women or cancers of the anus and penis in men. Two prophylactic vaccines have been proven to be highly effective in preventing the acquisition of HPV infection and the genital precancerous lesions caused by it. However, we do not know yet if a previously infected individual, once vaccinated, would be le... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
03/17/2025
Locations: McGill University - Division of Cancer Epidemiology, Montreal, Quebec
Conditions: Human Papillomavirus Infection
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
Active Not Recruiting
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/14/2025
Locations: Royal Inland Hospital, Kamloops, British Columbia +7 locations
Conditions: COVID-19
Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
Recruiting
The current recommendation for a full course of measles-mumps-rubella-(varicella) vaccine (MMR(V)) is two doses. The problem is, many individuals within the vaccinated cohort show antibody levels that are below the level considered to be protective, even after two doses of vaccine. Because of these waning antibody levels, it is currently unknown whether highly vaccinated populations are protected from infection against measles, mumps, rubella, or varicella should they be exposed to any of these... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Alberta, Edmonton, Alberta
Conditions: Vaccination Failure, Vaccine Response Impaired
Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)
Completed
The purpose of this trial is to test if treatment with the trial drug, tralokinumab, can affect the body's immune response to vaccines. The trial will also evaluate the efficacy of tralokinumab when it is given concomitantly with vaccines.
The trial includes a screening period of 2 to 6 weeks, a treatment period of 16 weeks (Weeks 0 to 16), and a 14-week off-treatment follow-up period for the assessment of safety (Weeks 16 to 30). Eligible subjects may transfer to an open-label, long-term trial... Read More
Gender:
ALL
Ages:
Between 18 years and 54 years
Trial Updated:
02/21/2025
Locations: Leo Pharma Investigational Site, Fort Smith, Arkansas +50 locations
Conditions: Atopic Dermatitis
COVID-19 Vaccine Boosters in Patients With CKD
Terminated
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral response following COVID-19 vaccination, in collaboration with 5 dialysis centers in Ontario and British Columbia, Canada .
Patients will be randomized to MODERNA or Pfizer-BioNTech COVID-19 vaccine, they may have received either MODERNA or Pfizer-BioNTech COVID-19 vacci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Scarborough Health Network, Scarborough, Ontario +2 locations
Conditions: Chronic Kidney Diseases, COVID-19
A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older
Completed
The purpose of this study is to evaluate the safety and efficacy of mRNA-1010 in preventing seasonal influenza in adults 50 years and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/20/2024
Locations: North Alabama Research Center, LLC, Athens, Alabama +232 locations
Conditions: Seasonal Influenza
Genomics and COVID-19 Vaccine Adverse Events
Recruiting
Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide.
Study hypothesis: there are genetic factors that contribute to increased risks of particul... Read More
Gender:
ALL
Ages:
Between 5 years and 99 years
Trial Updated:
12/03/2024
Locations: British Columbia Children's Hospital Research Institute, Vancouver, British Columbia
Conditions: Vaccine Adverse Reaction
1 - 12 of 103